Gestodene
Suppliers
Names
[ CAS No. ]:
60282-87-3
[ Name ]:
Gestodene
[Synonym ]:
(17a)-13-Ethyl-17-hydroxy-18,19-dinorpregna-4,15-dien-20-yn-3-one
SH B 331
GESTOGENE
(8R,9S,10R,13S,14S,17R)-13-Ethyl-17-ethynyl-17-hydroxy-1,2,6,7,8,9,10,11,12,13,14,17-dodecahydro-3H-cyclopenta[a]phenanthren-3-one
SH B 33
Femodene
EINECS 262-145-8
Gestodene
GESTODONE
17a-Ethynyl-13-ethyl-17b-hydroxy-4,15-gonadien-3-one
SHG 415 G
17a-Ethynyl-17b-hydroxy-18-methyl-4,15-estradien-3-one
Gynovin
MFCD00867858
Chemical & Physical Properties
[ Density]:
1.2±0.1 g/cm3
[ Boiling Point ]:
462.7±45.0 °C at 760 mmHg
[ Melting Point ]:
190-192°C
[ Molecular Formula ]:
C21H26O2
[ Molecular Weight ]:
310.430
[ Flash Point ]:
196.9±21.3 °C
[ Exact Mass ]:
310.193268
[ PSA ]:
37.30000
[ LogP ]:
3.65
[ Vapour Pressure ]:
0.0±2.6 mmHg at 25°C
[ Index of Refraction ]:
1.588
[ Storage condition ]:
-20°C Freezer
MSDS
Toxicological Information
CHEMICAL IDENTIFICATION
- RTECS NUMBER :
- JF7956000
- CHEMICAL NAME :
- 18,19-Dinorpregna-4,15-dien-20-yn-3-one, 13-ethyl-17-hydroxy-, (17-alpha)-
- CAS REGISTRY NUMBER :
- 60282-87-3
- LAST UPDATED :
- 199612
- DATA ITEMS CITED :
- 1
- MOLECULAR FORMULA :
- C21-H26-O2
- MOLECULAR WEIGHT :
- 310.47
HEALTH HAZARD DATA
ACUTE TOXICITY DATA
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Subcutaneous
- DOSE :
- 12 ug/kg
- SEX/DURATION :
- female 1 day(s) pre-mating
- TOXIC EFFECTS :
- Reproductive - Fertility - other measures of fertility
- REFERENCE :
- ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 35,459,1985
Safety Information
[ Symbol ]:
GHS08
[ Signal Word ]:
Warning
[ Hazard Statements ]:
H361
[ Precautionary Statements ]:
P280
[ Hazard Codes ]:
Xn
[ Risk Phrases ]:
62
[ Safety Phrases ]:
S22-S36/37
[ RIDADR ]:
NONH for all modes of transport
Synthetic Route
Precursor & DownStream
Precursor
DownStream
Articles
Obstet. Gynecol. Clin. North Am. 21(2) , 299-319, (1994)
Clofarabine was the latest new drug to be approved, in 2004, for relapsed or refractory acute lymphoblastic leukaemia (ALL). To investigate its value in the frontline treatment of ALL we applied clofa...
Gynecol. Endocrinol. 26(4) , 265-9, (2010)
The objective of the present study was to determine whether there is an increase in endometrial inflammation associated with the occurrence of breakthrough bleeding in patients using an oral contracep...
Gynecol. Endocrinol. 28(8) , 606-10, (2012)
We studied (1) the effects of oral contraceptive pills (OCPs) on hirsutism, hormonal and metabolic variables in 49 polycystic ovary syndrome patients without metabolic comorbidities and (2) the effect...